Interestingly miR-212, which was persistently 48-78-fold downregulated over the entire time period, is already known for its impact on radiosensitivity of glioma cells by targeting BRCA1, its immune modulating effect on primary human natural killer cells through IL-12 and its association with breast and prostate cancer, making it a particularly interesting target for further clinical investigation (supplement Table 1). This evidence concerns the gene BRCA1 and prostate cancer.